Singulex Collaborate with CHDI Foundation to Develop Biomarker Assays for Huntington’s Disease
News Apr 10, 2015
Singulex, Inc. has announced a collaboration agreement with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to rapidly developing drugs that will slow the progression of Huntington’s disease (HD). The collaboration will use Singulex’s proprietary Erenna® Immunoassay System to develop biomarkers to further Huntington’s disease research.
An article published online April 7th in the Journal of Clinical Investigation (JCI) outlines research from an international team of scientists who developed a new ultra-sensitive assay using the Singulex SMCTM Technology Erenna Immunoassay system that is able to detect mutant huntingtin protein (mHTT) in the cerebrospinal fluid (CSF) of HD patients, including some who carry the HD mutation but have not yet developed symptoms. The Singulex assay combines fluorescent antibodies with a laser detection chamber to count individual molecules of mHTT with a very low detection threshold, including both high specificity for mHTT and sensitivity to the femtomolar level.
“This research demonstrates the value of our SMC technology and its ability to measure previously undetectable levels of potential biomarkers, providing new insights into disease,” said Paul Wheeler, PhD, Vice President of Life Science Sales and Marketing at Singulex. “We are hopeful that this initial research and our further collaboration with CHDI will lead to the discovery of accepted biomarkers for use in the development and testing of new potential therapies for Huntington’s disease.”
In addition to detecting the protein in CSF for the first time, the researchers found that the level of mHTT was higher in people with more advanced disease. Additionally, the concentration of mHTT predicted the severity of movement and cognitive problems in patients.
“Quantifying disease-specific proteins in cerebrospinal fluid has been critical to the study and treatment of other neurodegenerative disorders, but until now mutant huntingtin protein has never been measured in CSF since it is present at such very low levels,” said Douglas Macdonald, PhD, Director of Drug Discovery and Development at CHDI. “With this new assay we hope that mutant huntingtin will prove to be a useful biomarker for the upcoming trials of huntingtin-lowering therapeutics.”
New Software Allows Mobile Monitoring of Breathing ProblemsNews
Researchers have developed new software that makes it possible to use low-cost, thermal cameras attached to mobile phones to track how fast a person is breathing.READ MORE
Agilent Announces Expanded Use of Cancer Diagnostic in the USNews
Agilent announced that the FDA has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma (UC) and of squamous cell carcinoma of the head and neck (SCCHN).READ MORE
Blood Test for Colitis Screening Could Reduce Dependence on ColonoscopyNews
A fast, simple blood test for ulcerative colitis using infrared spectroscopy could provide a cheaper, less invasive alternative for screening compared to colonoscopy, which is now the predominant test.READ MORE
Comments | 0 ADD COMMENT
13th Edition of International Conference on Pediatric Gastroenterology
Aug 02 - Aug 04, 2018